

( (S (NP-SBJ Health-care companies)
     (VP should
         (VP get
             (ADJP-PRD healthier)
             (PP-TMP in
		     (NP the third quarter))))
     .))
( (S (S-TPC-2 (NP-SBJ-1 Medical-supply houses)
	      (VP are
		  (VP expected
		      (S (NP-SBJ *-1)
			 (VP to
			     (VP report
				 (NP (NP earnings increases)
				     (PP of
					 (NP (NP (QP about 15) %)
					     (PP on
						 (NP average))))
				     (PP for
					 (NP the third quarter))))))
		      ,
		      (PP despite
			  (NP (NP sales increases)
			      (PP of
				  (NP (QP less than 10) %)))))))
     ,
     (NP-SBJ analysts)
     (VP say
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (S-PRP (NP-SBJ *-1)
	    (VP To
		(VP offset
		    (NP sluggish sales growth))))
     ,
     (NP-SBJ-1 companies)
     (VP have
	 (VP been
	     (VP (VP cutting
		     (NP staff)
		     ,
		     (PP (ADVP mostly)
			 through
			 (NP attrition)))
		 , 
		 and
		 (VP slowing
		     (NP (NP the growth)
			 (PP-LOC in
				 (NP research and development spending)))))))
     .))
( (S (NP-SBJ-3 (NP Sales growth)
	       (PP-TMP in
		       (NP the quarter)))
     (VP was
	 (VP slowed
	     (NP *-3)
	     (PP by
		 (NP-LGS (NP mounting pressure
			     (S *ICH*-2))
			 (PP from
			     (NP (NP groups)
				 (PP of
				     (NP buyers))
				 ,
				 (PP such as
				     (NP hospitals))))
			 ,
			 (S-2 (NP-SBJ *)
			      (VP to
				  (VP hold
				      (PRT down)
				      (NP prices))))))))
     .))
( (S (NP-SBJ-2 Suppliers)
     (VP were
         (ADVP also)
         (VP hurt
	     (NP *-2)
             (PP by
                 (NP-LGS (NP the stronger U.S. dollar)
			 ,
			 (SBAR (WHNP-1 which)
			       (S (NP-SBJ *T*-1)
				  (VP makes
				      (S (NP-SBJ (NP sales)
						 (ADVP-LOC abroad))
					 (ADJP-PRD more difficult)))))))))
     .))
( (S (PP-LOC In
	     (NP some cases))
     ,
     (NP-SBJ competition)
     (VP has
         (VP squeezed
             (NP margins)))
     .))
( (S (NP-SBJ Becton , Dickinson & Co.)
     ,
     (PP for
         (NP example))
     ,
     (VP faces
         (NP (NP stiff competition)
             (PP from
                 (NP a Japanese supplier))
	     (PP-LOC in
		     (NP the important syringe market))))
     .))
( (SINV (S-TPC-2 (NP-SBJ-1 The
			   (NAC-LOC Franklin Lakes
				    ,
				    N.J.
				    ,) 
			   company)
		 (VP (VP is
			 (VP expected
			     (S (NP-SBJ *-1)
				(VP to
				    (VP report
					(NP (NP sales growth)
					    (PP of
						(NP (QP only 5 % to 6 %)
						    *U*))))))))
		     , 
		     but
		     (VP should 
			 (ADVP-TMP still)
			 (VP maintain
			     (NP (NP earnings growth)
				 (PP of
				     (NP 10 %)))))))
	,
	(VP says
	    (SBAR 0
		  (S *T*-2)))
	(NP-SBJ (NP Jerry E. Fuller)
		,
		(NP (NP an analyst)
		    (PP with
			(NP Duff & Phelps Inc))))
	.))
( (S (S-ADV (NP-SBJ *-2)
	    (PP-LOC-PRD Among
			(NP (NP the first)
			    (PP of
				(NP the group))
			    (SBAR (WHNP-1 0)
				  (S (NP-SBJ *T*-1)
				     (VP to
					 (VP post
					     (NP results))))))))
     ,
     (NP-SBJ-2 Abbott Laboratories)
     (VP said
         (SBAR 0
               (S (NP-SBJ third-quarter net income)
                  (VP jumped
                      (NP-EXT 14 %)
                      (PP-DIR to
			      (NP (NP (QP $ 196 million) *U*)
				  , 
				  or
				  (NP (NP 88 cents)
				      (NP-ADV a share))))
                      ,
                      (PP-DIR from
			      (NP (NP (QP $ 172 million) *U*)
				  , 
				  or
				  (NP (NP 76 cents)
				      (NP-ADV a share))
				  ,)
			      (ADVP-TMP (NP a year)
					earlier))))))
     .))
( (S (NP-SBJ (NP Sales)
             (PP for
                 (NP (NP the company)
                     ,
                     (VP based
                         (NP *)
                         (PP-LOC-CLR in
				     (NP (NP Abbott Park)
					 ,
					 (NP Ill.)
					 ,))))))
     (VP rose
         (NP-EXT 8.3 %)
         (PP-DIR to
		 (NP (QP $ 1.31 billion) *U*))
         (PP-DIR from
		 (NP (QP $ 1.21 billion) *U*)))
     .))
( (S (NP-SBJ Baxter International Inc.)
     (NP-TMP yesterday)
     (VP reported
         (SBAR 0
               (S (NP-SBJ net)
                  (VP climbed
                      (NP-EXT 20 %)
                      (PP-TMP in
			      (NP the third period))
                      (PP-DIR to
			      (NP (NP (QP $ 102 million) *U*)
				  ,
				  or
				  (NP (NP 34 cents)
				      (NP-ADV a share))))
                      ,
                      (PP-DIR from
			      (NP (NP (QP $ 85 million) *U*)
				  , 
				  or
				  (NP (NP 28 cents)
				      (NP-ADV a share))
				  ,)
			      (ADVP-TMP (NP a year)
					earlier))))))
     .))
( (S (NP-SBJ (NP Sales)
             (PP for
                 (NP the
                     (NAC-LOC Deerfield
			      ,
			      Ill.
			      ,) 
		     company)))
     (VP rose
         (NP-EXT 5.8 %)
         (PP-DIR to
		 (NP (QP $ 1.81 billion) *U*))
         (PP-DIR from
		 (NP (QP $ 1.71 billion) *U*)))
     .))
( (S But
     (NP-SBJ-1 (ADJP not every)
	       company)
     (VP expects
         (S (NP-SBJ *-1)
            (VP to
                (VP report
                    (NP increased earnings)))))
     .))
( (S (NP-SBJ C.R. Bard Inc.)
     (NP-TMP yesterday)
     (VP said
         (SBAR 0
               (S (NP-SBJ third-quarter net)
                  (VP plunged
                      (NP-EXT 51 %)
                      (PP-DIR to
			      (NP (NP (QP $ 9.9 million) *U*)
				  ,
				  or
				  (NP (NP 18 cents)
				      (NP-ADV a share))))
                      ,
                      (PP-DIR from
			      (NP (NP (QP $ 20 million) *U*)
				  ,
				  or
				  (NP (NP 35 cents)
				      (NP-ADV a share))
				  ,)
			      (ADVP-TMP (NP a year)
					earlier))))))
     .))
( (S (NP-SBJ Sales)
     (VP fell
         (NP-EXT 1.2 %)
         (PP-DIR to
		 (NP (QP $ 190.1 million) *U*))
         (PP-DIR from
		 (NP (QP $ 192.5 million) *U*)))
     .))
( (S (NP-SBJ The
             (NAC-LOC Murray Hill
		      ,
		      N.J.
		      ,) 
	     company)
     (VP said
         (SBAR 0
               (S (NP-SBJ full-year earnings)
                  (VP may
                      (VP be
                          (ADVP-PRD off
                                    (NP (NP 33 cents)
                                        (NP-ADV a share)))
			  (SBAR-PRP because
				    (S (NP-SBJ the company)
				       (VP removed
					   (NP a catheter)
					   (PP-CLR from
						   (NP the market))))))))))
     .))
( (S (PP-TMP In
	     (NP 1988))
     ,
     (NP-SBJ the company)
     (VP earned
         (NP (NP $ 1.38 *U*)
             (NP-ADV a share)))
     .))
( (S (NP-SBJ The Food and Drug Administration)
     (VP had
         (VP raised
             (NP (NP questions)
                 (PP about
                     (NP (NP the device 's)
                         design)))))
     .))
( (S (NP-SBJ Some analysts)
     (VP add
         (SBAR that
               (S (NP-SBJ-1 third-party pressures
			    (S (NP-SBJ *)
			       (VP to
				   (VP reduce
				       (NP health costs)))))
                  (VP will
                      (VP continue
                          (S (NP-SBJ *-1)
                             (VP to
                                 (VP bedevil
                                     (NP (NP companies ')
                                         bottom lines)))))))))
     .))
( (SINV (S-TPC-2 (NP-SBJ (NP Takeover speculation)
			 ,
			 (SBAR (WHNP-1 which)
			       (S (NP-SBJ *T*-1)
				  (VP has
				      (VP been
					  (VP buoying
					      (NP (NP stocks)
						  (PP of
						      (NP supply houses))))))))
			 ,)
		 (VP may
		     (ADVP also)
		     (VP ease)))
	,
	(VP says
	    (SBAR 0
		  (S *T*-2)))
	(NP-SBJ (NP Peter Sidoti)
		,
		(NP (NP an analyst)
		    (PP with
			(NP Drexel Burnham Lambert Inc))))
	.))
( (S ``
     (S-TPC-2 (SBAR-TMP As
			(S (NP-SBJ that)
			   (VP wanes)))
	      ,
	      (NP-SBJ-1 you)
	      (VP 're
		  (VP going
		      (S (NP-SBJ *-1)
			 (VP to
			     (VP see
				 (S (NP-SBJ the stocks)
				    (ADVP probably)
				    (VP wane
					(ADVP as well)))))))))
     ,
     ''
     (NP-SBJ he)
     (VP says
	 (S *T*-2))
     .))
( (S (NP-SBJ Hospitals companies)
     ,
     (ADVP-TMP meanwhile)
     ,
     (VP are
         (VP reporting
             (NP improved earnings)))
     .))
( (S (S-ADV (NP-SBJ-1 *-2)
	    (VP Bolstered
		(NP *-1)
		(PP by
		    (NP-LGS (NP strong performances)
			    (PP by
				(NP its psychiatric hospitals))))))
     ,
     (NP-SBJ-2 (NP National Medical Enterprises Inc.)
	       ,
	       (NP-LOC Los Angeles)
	       ,)
     (VP reported
	 (NP (NP net income)
	     (PP of
		 (NP (NP (NP (QP $ 50 million) *U*)
			 , 
			 or
			 (NP (NP 65 cents)
			     (NP-ADV a share)))
		     (ADVP *ICH*-3)))
	     ,
	     (PP for
		 (NP (NP the first quarter)
		     (VP ended
			 (NP-TMP Aug. 31))))
	     ,
	     (ADVP-3 up
		     (PP from
			 (NP (NP (QP $ 41 million) *U*)
			     , 
			     or
			     (NP (NP 56 cents)
				 (NP-ADV a share))
			     ,)
			 (ADVP-TMP (NP a year)
				   earlier)))))
     .))
( (S (NP-SBJ (NP Humana Inc.)
             ,
             (NP-LOC (NP Louisville)
		     ,
		     (NP Ky.))
             ,)
     (ADVP also)
     (VP reported
         (NP (NP favorable results)
	     ,
             (PP with
                 (NP (NP net income)
                     (PP of
                         (NP (NP (NP (QP $ 66.7 million) *U*)
				 ,
				 or
				 (NP 66 cents))
			     (ADVP *ICH*-1)))
                     ,
                     (PP-TMP in
			     (NP (NP the fourth quarter)
				 (VP ended
				     (NP-TMP Aug. 31))))
                     ,
                     (ADVP-1 up
			     (PP from
				 (NP (NP (QP $ 58.2 million) *U*)
				     ,
				     or
				     (NP 59 cents)
				     ,)
				 (ADVP-TMP (NP a year)
					   earlier)))))))
     .))
( (S (NP-SBJ Analysts)
     (VP say
         (SBAR 0
               (S (NP-SBJ (NP the handful)
			  (PP of
			      (NP hospital companies))
                          (SBAR (WHNP-1 that)
                                (S (NP-SBJ-2 *T*-1)
                                   (VP are
                                       (ADVP-TMP still)
				       (VP (ADVP-MNR publicly)
					   traded
					   (NP *-2))))))
                  (VP are
                      (VP benefiting
                          (PP-CLR from
				  (NP several trends)))))))
     .))
( (S (S-ADV (NP-SBJ *)
	    (ADJP-PRD Most important))
     ,
     (NP-SBJ hospital admission rates)
     (VP are
	 (VP stabilizing
	     (PP-TMP after
		     (NP (NP several years)
			 (PP of
			     (NP decline))))))
     .))
( (S (ADVP Moreover)
     ,
     (NP-SBJ companies)
     (VP (VP have
	     (VP sold
		 (ADVP-CLR off)
		 (NP (NP many)
		     (PP of
			 (NP their
			     smaller , less-profitable
			     hospitals)))))
	 and
	 (VP have
	     (VP completed
		 (NP painful restructurings))))
     .))
( (S (NP-SBJ-1 (NP Humana 's)
               revenues)
     ,
     (PP for
         (NP example))
     ,
     (VP are
         (VP being
             (VP boosted
                 (NP *-1)
                 (PP by
                     (NP-LGS (NP large increases)
			     (PP-LOC in
				     (NP (NP enrollments)
					 (PP in
					     (NP (NP the company 's)
						 health maintenance organizations)))))))))
     .))
( (SINV (VP Says
	    (S *ICH*-1))
	(NP-SBJ (NP Todd Richter)
		,
		(NP (NP an analyst)
		    (PP with
			(NP Dean Witter Reynolds))))
	:
	``
	(S-1 (NP-SBJ (NP The shakeout)
		     (PP-LOC in
			     (NP the
				 (ADJP publicly traded)
				 companies)))
	     (VP is
		 (ADJP-PRD over)))
	.))
